網(wǎng)絡(luò)出版時(shí)間:2014-12-4 13:45網(wǎng)絡(luò)出版地址:http://www.cnki.net/kcms/doi/10.3969/j.issn.1001-1978.2015.01.018.html
PLCE1調(diào)控p53誘導(dǎo)食管癌細(xì)胞凋亡的實(shí)驗(yàn)研究
李昀,張軍航, 安軍,何錦園,黃邵洪
(中山大學(xué)附屬第三醫(yī)院心胸外科,廣東 廣州510630)
中國(guó)圖書分類號(hào):R329.25;R345.61;R735.102.2;R977.3
摘要:目的探討磷脂酶Cε1(PLCE1)基因抑制食管癌細(xì)胞凋亡的作用機(jī)制。方法選用人食管癌細(xì)胞株OE33和CP-C作為研究對(duì)象。采用qRT-PCR、Western blot法分別檢測(cè)轉(zhuǎn)染PLCE1 siRNA前、后食管癌細(xì)胞OE33和CP-C中PLCE1、p53 mRNA和蛋白水平的表達(dá);甲基化特異性PCR重亞硫酸鹽法檢測(cè)p53啟動(dòng)子區(qū)甲基化狀態(tài);流式細(xì)胞儀檢測(cè)細(xì)胞凋亡。結(jié)果食管癌細(xì)胞株OE33和CP-C均高表達(dá)PLCE1,抑制PLCE1表達(dá)后食管癌細(xì)胞CP-C中p53表達(dá)上調(diào)并促進(jìn)p53去甲基化,細(xì)胞凋亡明顯增加。結(jié)論P(yáng)LCE1通過(guò)促進(jìn)p53啟動(dòng)子區(qū)甲基化抑制p53 的表達(dá),從而抑制食管癌細(xì)胞凋亡。
關(guān)鍵詞:食管癌;磷脂酶Cε1;p53;細(xì)胞凋亡;小干擾RNA;表觀遺傳學(xué)
doi:10.3969/j.issn.1001-1978.2015.01.018
文章編號(hào):
文獻(xiàn)標(biāo)志碼:A1001-1978(2015)01-0082-05
收稿日期:2014-09-20,修回日期:2014-10-12
基金項(xiàng)目:中山大學(xué)“985工程”工程項(xiàng)目(No 82000-31101301)
作者簡(jiǎn)介:李昀(1981-),男,博士,主治醫(yī)師,研究方向:胸部腫瘤發(fā)病機(jī)制,E-mail: yunmao@163.com;
通訊作者黃邵洪(1976-),男,博士,主治醫(yī)師,研究方向:胸部腫瘤基礎(chǔ)與臨床,,E-mail: legendhuang@126.com
Abstract:AimTo investigate the role of phospholipase C epsilon 1 (PLCE1) in modulating the apoptotic mechanism in esophageal cancer (Eca) cells. MethodsEca cell lines, OE33 and CP-C cells were cultured to assess the expression of PLCE1. siRNA suppress expression of PLCE1. The expression of PLCE1 and p53 was evaluated by quantitative real time PCR and Western blot. Methylation analyses of p53 were performed by bisulfite conversion of genomic DNA. Apoptosis was assessed by flow cytometry. ResultsOE33 and CP-C cells expressed high levels of PLCE1. Knockdown of PLCE1 markedly increased the expression and hypomethylation of p53, and increased the frequency of apoptosis. ConclusionPLCE1 suppresses apoptosis of Eca cells via promoting p53 promoter methylation and inhibiting expression of p53.
食管癌是我國(guó)常見的惡性腫瘤之一,發(fā)病率居惡性腫瘤第5位,死亡率居第4位[1],5年生存率低于15%[2],但其發(fā)病機(jī)制尚不十分清楚,且目前的治療效果不甚理想。
在正常生理狀態(tài)下,細(xì)胞分化與凋亡維持在平衡狀態(tài)。當(dāng)細(xì)胞不能接受信號(hào)啟動(dòng)凋亡,處于無(wú)限生長(zhǎng)狀態(tài)就可能引起腫瘤的發(fā)生。如抑癌基因p53表達(dá)降低與多種腫瘤發(fā)生密切相關(guān),包括食管癌。p53可引起細(xì)胞周期阻滯、凋亡及維持基因組穩(wěn)定性從而抑制腫瘤[3],但是p53在食管癌中失活的機(jī)制有待進(jìn)一步闡明。
磷脂酶Cε1(phospholipase C epsilon 1,PLCE1)是近年發(fā)現(xiàn)的磷脂酶C家族的新成員,其定位的染色體是最近發(fā)現(xiàn)的食管鱗癌易感位點(diǎn)。PLCE1在細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)過(guò)程中起重要作用,調(diào)節(jié)細(xì)胞生長(zhǎng)、增殖、分化,影響細(xì)胞骨架改變、細(xì)胞運(yùn)動(dòng)、細(xì)胞凋亡、腫瘤生長(zhǎng)及發(fā)展等生物學(xué)行為。本研究擬通過(guò)檢測(cè)PLCE1在食管癌細(xì)胞株OE33和CP-C中的表達(dá),驗(yàn)證改變PLCE1表達(dá)對(duì)食管癌細(xì)胞功能的影響,初步闡明PLCE1通過(guò)p53途徑在食管癌細(xì)胞中發(fā)揮作用的機(jī)制。
1材料與方法
1.1試劑PLCE1抗體(sc-28402)、p53抗體(sc-6243)、兔抗羊(sc-276)及羊抗兔二抗(sc-2004)、β-actin抗體(sc-130301)、PLCE1 siRNA(sc-44024)和對(duì)照siRNA(sc-37007)購(gòu)自Santa Cruz Biotech。Annexin V試劑盒購(gòu)自Sigma。DNA純化盒購(gòu)自Promega。甲基化檢測(cè)盒購(gòu)自Clontech。轉(zhuǎn)染試劑lipofectamine2000、質(zhì)粒抽提試劑盒、qRT-PCR和Western blot所用試劑均購(gòu)自Invitrogen。PLCE1過(guò)表達(dá)載體(pcDNA3.1-PLCE1 )由中山大學(xué)腫瘤醫(yī)院劉曉萍博士惠贈(zèng)。
1.2細(xì)胞株、培養(yǎng)及轉(zhuǎn)染食管癌細(xì)胞株OE33、CP-C及正常細(xì)胞株HEK293均購(gòu)于中科院上海細(xì)胞庫(kù),用含10%胎牛血清、2 mmol·L-1谷氨酰胺、100 kU·L-1青霉素和0.1%鏈霉素的DMEM細(xì)胞培養(yǎng)液,在二氧化碳培養(yǎng)箱內(nèi)(37℃、5%CO2、飽和濕度)連續(xù)培養(yǎng)并傳代。培養(yǎng)液每3 d換液1次。當(dāng)細(xì)胞長(zhǎng)至瓶底80%時(shí)進(jìn)行處理。細(xì)胞轉(zhuǎn)染,根據(jù)轉(zhuǎn)染試劑說(shuō)明書進(jìn)行,分別將siRNA及對(duì)照無(wú)關(guān)系列或PLCE1過(guò)表達(dá)載體、對(duì)照載體轉(zhuǎn)染至食管癌細(xì)胞中,并設(shè)空白對(duì)照;轉(zhuǎn)染48 h后提取總RNA或進(jìn)行細(xì)胞凋亡檢測(cè),轉(zhuǎn)染72 h后提取細(xì)胞總蛋白。
1.3實(shí)時(shí)熒光定量PCR法(qRT-PCR)TRIzol法提取細(xì)胞總RNA并定量;按試劑盒說(shuō)明進(jìn)行逆轉(zhuǎn)錄合成cDNA。應(yīng)用實(shí)時(shí)熒光定量RT-PCR檢測(cè),β-actin作為內(nèi)參。PCR引物:p53:上游引物5′-GGAAATCTCACCCCATCCCA-3′,下游引物 5′-CAGTAAGCCAAGATCACGCC-3′;PLCE1:上游引物5′-GAGCTGCAATCGAAGTCTGG-3′, 下游引物 5′-AAGGCCTTCTGTGAGTCCTC-3′; β-actin(上游引物5′-CTCCATCCTGGCCTCGCTGT-3′, 下游引物 5′-GCTGTCACCTTCACCGTTCC-3′)。反應(yīng)體系為20 μL,反應(yīng)條件為95℃ 3 min預(yù)變性,95℃ 10 s,55℃ 30 s,39個(gè)循環(huán),并在每個(gè)循環(huán)延伸末端點(diǎn)收集熒光信號(hào),繪制擴(kuò)增曲線,基因的表達(dá)量用2-ΔΔCt表示。
1.4Western blot預(yù)冷PBS洗滌細(xì)胞3次,加入全蛋白裂解液后冰上裂解10 min收集蛋白。將抽提蛋白用BCA法定量后,取50 μg于100 V泳道進(jìn)行SDS-PAGE;電泳結(jié)束后,以90 V、90 min將蛋白轉(zhuǎn)移至PVDF膜; 5%TBS牛奶室溫封閉1 h,孵育一抗羊抗p53(1 ∶1 000)、兔抗PLCE1 (1 ∶500)4 ℃過(guò)夜,二抗(兔抗羊1 ∶5 000、羊抗兔1 ∶2 000)室溫孵育1 h。每次抗體孵育后用TBST洗膜15 min,共3次。ECL試劑盒進(jìn)行發(fā)光反應(yīng),壓片、顯影、定影,觀察蛋白印跡并進(jìn)行圖像分析。
1.5細(xì)胞凋亡檢測(cè)根據(jù)試劑盒進(jìn)行操作,收集CP-C細(xì)胞先用Annexin V染色,再用碘化丙啶 (propidium iodide,PI,5 mg·L-1,15 min)染色。流式細(xì)胞儀檢測(cè)細(xì)胞凋亡率,PI+細(xì)胞首先被檢出,Annexin V+細(xì)胞頻數(shù)在剩余細(xì)胞中確定。
2結(jié)果
2.1PLCE1在食管癌細(xì)胞中高表達(dá)本研究檢測(cè)了食管癌細(xì)胞株OE33和CP-C細(xì)胞中PLCE1的表達(dá)。結(jié)果發(fā)現(xiàn),OE33和CP-C細(xì)胞中PLCE1的mRNA和蛋白表達(dá)水平明顯高于正常細(xì)胞HEK293,差異有統(tǒng)計(jì)學(xué)意義(P<0.01)(Fig 1)。
2.2抑制PLCE1促進(jìn)食管癌細(xì)胞凋亡將PLCE1 siRNA轉(zhuǎn)染至食管癌CP-C細(xì)胞中,抑制PLCE1的表達(dá),檢測(cè)細(xì)胞凋亡情況。結(jié)果表明,PLCE1 siRNA組細(xì)胞凋亡率最高,空白對(duì)照組(mock)與轉(zhuǎn)染無(wú)關(guān)系列組(scramble)差異無(wú)顯著性,PLCE1 siRNA與其它兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.01)(Fig 2)。
2.3抑制食管癌細(xì)胞中PLCE1表達(dá)可促進(jìn)p53表達(dá)進(jìn)一步采用qRT-PCR與Western blot檢測(cè)PLCE1對(duì)食管癌CP-C細(xì)胞中p53表達(dá)的影響。結(jié)果發(fā)現(xiàn),抑制CP-C細(xì)胞中PLCE1的表達(dá)后,p53表達(dá)上調(diào)。而在HEK293細(xì)胞過(guò)表達(dá)PLCE1后,p53表達(dá)下調(diào)(Fig 3)。
2.4PLCE1調(diào)節(jié)p53啟動(dòng)子甲基化甲基化特異性PCR結(jié)果提示HEK293細(xì)胞中甲基化狀態(tài)的p53 小于20%,而CP-C細(xì)胞中,甲基化狀態(tài)的p53 大于75%。干擾CP-C細(xì)胞中PLCE1表達(dá)后,p53啟動(dòng)子甲基化狀態(tài)明顯下調(diào),而HEK293細(xì)胞過(guò)表達(dá)PLCE1后,p53啟動(dòng)子高甲基化(Fig 4)。
3討論
食管癌是我國(guó)常見的惡性腫瘤之一,其發(fā)生發(fā)展的分子機(jī)制多樣。研究表明,基因突變、等位基因高頻率雜合性缺失(LOH)、抑癌基因失活等均可促進(jìn)食管癌的發(fā)生發(fā)展。如DNA聚合酶β(DNA polymerase β,DNA polβ)啟動(dòng)子發(fā)生突變,在食管癌細(xì)胞中表達(dá)增加[4]。抑癌基因p53所在染色體17p13區(qū)域存在LOH,導(dǎo)致表達(dá)失活,食管癌發(fā)生[5]。
Fig 1 Eca cells express high levels of PLCE1( n=26)
A: The bars indicate the relative mRNA levels of PLCE1 of OE33 and CP-C cells; B1-B2: The expression of PLCE1 protein was detected by Western blot,**P<0.01vsHEK293 cell.
Fig 2 Suppression of PLCE1 induces apoptosis in CP-C cells( n=26)
A: The dot plots indicate the frequency of dead CP-C cells (PI+) and apoptotic cells (Annexin V+); B-C: The bars indicate the summarized data of dead cells (B) and apoptotic cells (C),**P<0.01vsmock.
最近兩項(xiàng)大樣本全基因組關(guān)聯(lián)研究(GWAS)發(fā)現(xiàn)了新的食管癌易感基因位點(diǎn)rs2274223,定位于染色體10q23的PLCE1基因[6-7]。PLCE1是近年發(fā)現(xiàn)的磷脂酶C家族的新成員,在細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)過(guò)程中起重要作用,調(diào)節(jié)細(xì)胞生長(zhǎng)、增殖、分化,影響細(xì)胞骨架改變、細(xì)胞運(yùn)動(dòng)、細(xì)胞凋亡、腫瘤生長(zhǎng)及發(fā)展等生物學(xué)行為[8-9]。目前有關(guān)食管癌中PLCE1表達(dá)水平的報(bào)道結(jié)果不盡一致,Chen 等[10]報(bào)道哈薩克族食管癌患者中PLCE1表達(dá)升高,其表達(dá)水平與腫瘤分期正相關(guān)。Hu等[11]則報(bào)道食管癌組織中PLCE1 mRNA表達(dá)水平下降,免疫染色分析提示基因型rs2274223 GG者 PLCE1染色分?jǐn)?shù)低于AG型。而我們的研究發(fā)現(xiàn)PLCE1在食管癌細(xì)胞OE33和CP-C中均高表達(dá),與chen的研究結(jié)果一致。分析出現(xiàn)這種情況的可能原因有:(1)樣本數(shù)有差異;(2)種族差異;(3)環(huán)境因素。
表觀遺傳學(xué)調(diào)控是當(dāng)今生命科學(xué)關(guān)注的前沿,在基因調(diào)控中起重要作用,其涉及的機(jī)制主要包括DNA甲基化、miRNA、組蛋白修飾及染色質(zhì)重塑等。DNA甲基化是指DNA在甲基轉(zhuǎn)移酶(DNA methyltransferase,DMT) 的催化下,以s-腺苷甲硫氨酸(SAM)為甲基供體,將甲基轉(zhuǎn)移到特定的堿基上的過(guò)程。在哺乳動(dòng)物中DNA甲基化主要發(fā)生在5′-CpG-3′的C上生成5-甲基胞嘧啶(5mC)。在真核生物中發(fā)現(xiàn)了3類DNA甲基轉(zhuǎn)移酶(Dnmt1、Dnmt2、Dnmt3a、Dnmt3b)。Dnmt1是一種維持性甲基化酶;Dnmt2可與DNA上特異位點(diǎn)結(jié)合;Dnmt3a和Dnmt3b是重新甲基化酶,它們使去甲基化的CpG位點(diǎn)重新甲基化,即參與DNA的從頭甲基化。眾多研究發(fā)現(xiàn),在腫瘤發(fā)生發(fā)展的過(guò)程中,DNA甲基化能關(guān)閉某些抑癌基因的活性,去甲基化則誘導(dǎo)了癌基因的重新活化和表達(dá)[12]。本研究發(fā)現(xiàn),CP-C細(xì)胞中甲基化狀態(tài)的p53 大于75%,而抑制CP-C細(xì)胞中PLCE1的表達(dá)后,p53表達(dá)上調(diào),p53啟動(dòng)子甲基化狀態(tài)明顯下調(diào),提示抑癌基因p53啟動(dòng)子高甲基化在食管癌的發(fā)生發(fā)展中發(fā)揮重要作用。
細(xì)胞凋亡下調(diào)是腫瘤發(fā)生的重要原因之一,眾多因子參與細(xì)胞凋亡的調(diào)控,如TNF-α促進(jìn)細(xì)胞凋亡[13],GS-459679抑制細(xì)胞凋亡[14],SCO2 (細(xì)胞色素C氧化酶2合成物)可誘導(dǎo)p53表達(dá)從而促進(jìn)細(xì)胞凋亡[15]。大量研究證實(shí)[16],p53與細(xì)胞凋亡密切相關(guān),p53能通過(guò)高爾基復(fù)合體轉(zhuǎn)運(yùn)Fas短暫促進(jìn)血管平滑肌細(xì)胞表面Fas表達(dá)并促進(jìn)Fas-FADD的結(jié)合誘導(dǎo)凋亡。腫瘤細(xì)胞過(guò)表達(dá)p53能誘導(dǎo)細(xì)胞凋亡,而特異性抑制劑分別抑制caspase-8及caspase-9后均能抑制這種p53依賴的凋亡,表明p53對(duì)死亡受體通路和線粒體通路均有影響[17]。通過(guò)本研究發(fā)現(xiàn),抑制食管癌細(xì)胞中PLCE1的表達(dá)可促進(jìn)p53的表達(dá),進(jìn)而促進(jìn)食管癌CP-C細(xì)胞凋亡。
綜上所述,我們推測(cè), PLCE1通過(guò)促進(jìn)p53啟動(dòng)子區(qū)甲基化抑制p53 的表達(dá),從而抑制食管癌細(xì)胞凋亡。PLCE1可能成為食管癌治療的新靶點(diǎn)。
Fig 3 Inhibition of PLCE1 upregulates expression of p53 in Eca cells( n=26)
A: PLCE1 inhibited expression of p53 mRNA; B1-B2: The levels of p53 protein was detected by Western blot. C1-C2: The Western blot showed the expression of PLCE1 in HEK293 cells. D1-D2: The PLCE1 gene knockdown results. Mock: Untreated group; siRNA: Treated with PLCE1 siRNA. scramble: Treated with control siRNA. HEK293 cells were treated with mock (HEK293a), or pPLCE1 (PLCE1 overexpression plasmid) (HEK293b), or control plasmid (HEK293c).**P<0.01vsmock.
Fig 4PLCE1 induces p53 promoter methylation(n=26)
HEK:HEK293;PLCE1-d: PLCE1 siRNA;csiRNA: Scramble;PLCE1 O-ex: PLCE1 plasmid;M: Methylated primer;U: Un-methylated primer.**P<0.01vsHEK cells
參考文獻(xiàn):
[1]Chen W, He Y, Zheng R, et al. Esophageal cancer incidence and mortality in China, 2009 [J].JThoracicDis, 2013,5(1):19-26.
[2]Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [J].CACancerJClin, 2005,55(1):10-30.
[3]Turner N, Moretti E, Siclari O, et al. Targeting triple negative breast cancer: is p53 the answer[J]?CancerTreatmRev,2013,39(5):541-50.
[4]Li M, Zang W, Wang Y, et al. DNA polymerase beta promoter mutations and transcriptional activity in esophageal squamous cell carcinoma [J].TumourBiol,2013,34(5):3259-63.
[5]Egashira A, Morita M, Yoshida R, et al. Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival: analyses of gene mutations, protein expression, and loss of heterozygosity in Japanese patients [J].JSurgOncol,2011,104(2):169-75.
[6]Wu C, Hu Z, He Z, et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations [J].NatGenet, 2011,43(7):679-84.
[7]Wang L D, Zhou F Y, Li X M, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54 [J].NatGenet,2010,42(9):759-63.
[8]Ada-Nguema A S, Xenias H, Hofman J M, et al. The small GTPase R-Ras regulates organization of actin and drives membrane protrusions through the activity of PLCepsilon [J].JCellSci, 2006,119(Pt 7):1307-19.
[9]Lad Y, McHugh B, Hodkinson P S, et al. Phospholipase C epsilon suppresses integrin activation [J].JBiolChem, 2006,281(40):29501-12.
[10]Chen Y Z, Cui X B, Hu J M, et al. Overexpression of PLCE1 in Kazakh esophageal squamous cell carcinoma: implications in cancer metastasis and aggressiveness [J].APMIS, 2013,121(10):908-18.
[11]Hu H, Yang J, Sun Y, et al. Putatively functional PLCE1 variants and susceptibility to esophageal squamous cell carcinoma (ESCC): a case-control study in eastern Chinese populations [J].AnnSurgOncol, 2012,19(7):2403-10.
[12]Suzuki H, Maruyama R, Yamamoto E, et al. Epigenetic alteration and microRNA dysregulation in cancer [J].FrontGenet, 2013,4:258.
[13]Chen F H, Lu N, Zhang H W, et al. LYG-202 augments tumor necrosis factor-alpha-induced apoptosis via attenuating casein kinase 2-dependent nuclear factor-kappaB pathway in HepG2 cells [J].MolPharmacol, 2012,82(5):958-71.
[14]Toldo S, Breckenridge D G, Mezzaroma E, et al. Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse [J].JAmHeartAssoci,2012,1(5):e002360.
[15]Stiburek L, Vesela K, Hansikova H, et al. Loss of function of Sco1 and its interaction with cytochrome c oxidase[J].AmJPhysiol, 2009,296(5):C1218-26.
[16]Salvesen G S, Dixit V M. Caspases: intracellular signaling by proteolysis [J].Cell, 1997,91(4):443-6.
[17]Bennett M, Macdonald K, Chan S W, et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis [J].Science,1998,282(5387):290-3.
PLCE1 modulates p53 expression and apoptosis in esophageal cancer cells
LI Yun, ZHANG Jun-hang, AN Jun, HE Jin-yuan, HUANG Shao-hong
(DeptofCardiothoracicSurgery,theThirdAffiliatedHospitalofSunYat-senUniversity,Guangzhou510630,China)
Key words: esophageal cancer; phospholipase cepsilon 1; p53; apoptosis; small interfering RNA; epigenomics